243 related articles for article (PubMed ID: 18417306)
1. Enhancing effect of Labrafac Lipophile WL 1349 on oral bioavailability of hydroxysafflor yellow A in rats.
Wang S; Sun M; Ping Q
Int J Pharm; 2008 Jun; 358(1-2):198-204. PubMed ID: 18417306
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and excretion of hydroxysafflor yellow A, a potent neuroprotective agent from safflower, in rats and dogs.
Chu D; Liu W; Huang Z; Liu S; Fu X; Liu K
Planta Med; 2006 Apr; 72(5):418-23. PubMed ID: 16557455
[TBL] [Abstract][Full Text] [Related]
3. A novel oral preparation of hydroxysafflor yellow A base on a chitosan complex: a strategy to enhance the oral bioavailability.
Ma GN; Yu FL; Wang S; Li ZP; Xie XY; Mei XG
AAPS PharmSciTech; 2015 Jun; 16(3):675-82. PubMed ID: 25511808
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic properties of hydroxysafflor yellow A in healthy Chinese female volunteers.
Yang Z; Yang J; Jia Y; Tian Y; Wen A
J Ethnopharmacol; 2009 Jul; 124(3):635-8. PubMed ID: 19570628
[TBL] [Abstract][Full Text] [Related]
5. Enhanced effect and mechanism of water-in-oil microemulsion as an oral delivery system of hydroxysafflor yellow A.
Qi J; Zhuang J; Wu W; Lu Y; Song Y; Zhang Z; Jia J; Ping Q
Int J Nanomedicine; 2011; 6():985-91. PubMed ID: 21720510
[TBL] [Abstract][Full Text] [Related]
6. Determination of hydroxysafflor yellow A in rat plasma and tissues by high-performance liquid chromatography after oral administration of safflower extract or safflor yellow.
Li Y; Zhang ZY; Zhang JL
Biomed Chromatogr; 2007 Mar; 21(3):326-34. PubMed ID: 17221936
[TBL] [Abstract][Full Text] [Related]
7. [Studies on pharmacokinetics of hydroxysafflor yellow A in Carthamus tinctorius and its compound preparation in rat].
Tang J; Ouyang Z; Feng X; Fang J; Cao X
Zhongguo Zhong Yao Za Zhi; 2011 Aug; 36(16):2246-9. PubMed ID: 22097340
[TBL] [Abstract][Full Text] [Related]
8. Effect of adsorbents on the absorption of lansoprazole with surfactant.
Ito Y; Arai H; Uchino K; Iwasaki K; Shibata N; Takada K
Int J Pharm; 2005 Jan; 289(1-2):69-77. PubMed ID: 15652200
[TBL] [Abstract][Full Text] [Related]
9. A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of hydroxysafflor yellow A in human plasma: application to a pharmacokinetic study.
Wen A; Yang J; Jia Y; Yang Z; Tian Y; Wu Y; Wang Z; He Z
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Dec; 876(1):41-6. PubMed ID: 18964371
[TBL] [Abstract][Full Text] [Related]
10. Formulation and evaluation of ubidecarenone transdermal delivery systems.
Jung SY; Kang EY; Choi YJ; Chun IK; Lee BK; Gwak HS
Drug Dev Ind Pharm; 2009 Sep; 35(9):1029-34. PubMed ID: 19365779
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetic effect of Sappan Lignum on hydroxysafflor yellow A in Carthami Flos].
Xia L; Chen XM; Peng LR; Wang SX; Wang XW; Zuo Y; Zhang P; Liu QS; Zheng XH
Zhongguo Zhong Yao Za Zhi; 2013 Jan; 38(2):269-72. PubMed ID: 23672054
[TBL] [Abstract][Full Text] [Related]
12. [Effect of constituents combination on pharmacokinetics of Shuxiong tablet].
Qi J; Ping Q; Li J; Zhuang J; Song Y
Zhongguo Zhong Yao Za Zhi; 2009 Sep; 34(17):2241-6. PubMed ID: 19943495
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of hydroxysafflor yellow A: in vivo and in vitro studies.
Zhu H; Wang Z; Ma C; Tian J; Fu F; Li C; Guo D; Roeder E; Liu K
Planta Med; 2003 May; 69(5):429-33. PubMed ID: 12802724
[TBL] [Abstract][Full Text] [Related]
14. The mechanisms for enhanced oral absorption of hydroxysafflor yellow A by chuanxiong volatile oil.
Qi J; Sun M; Ping Q; Zhuang J; Li J; Peddie F; Song Y
Planta Med; 2010 May; 76(8):786-92. PubMed ID: 20033864
[TBL] [Abstract][Full Text] [Related]
15. Self-microemulsifying drug delivery system for improved oral bioavailability of dipyridamole: preparation and evaluation.
Guo F; Zhong H; He J; Xie B; Liu F; Xu H; Liu M; Xu C
Arch Pharm Res; 2011 Jul; 34(7):1113-23. PubMed ID: 21811918
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of enhanced oral absorption of hydrophilic drug incorporated in hydrophobic nanoparticles.
Lv LZ; Tong CQ; Yu J; Han M; Gao JQ
Int J Nanomedicine; 2013; 8():2709-17. PubMed ID: 23935363
[TBL] [Abstract][Full Text] [Related]
17. Solid lipid nanoparticles as carriers for oral delivery of hydroxysafflor yellow A.
Zhao B; Gu S; Du Y; Shen M; Liu X; Shen Y
Int J Pharm; 2018 Jan; 535(1-2):164-171. PubMed ID: 29107614
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profiles of hydroxysafflor yellow A following intravenous administration of its pure preparations in healthy Chinese volunteers.
Li CY; Yin JG; Zhang J; Wang XX; Xu MJ; Liu F; Zou JD; Ju WZ
J Ethnopharmacol; 2015 Mar; 162():225-30. PubMed ID: 25576896
[TBL] [Abstract][Full Text] [Related]
19. Enhanced absorption of hydroxysafflor yellow A using a self-double-emulsifying drug delivery system: in vitro and in vivo studies.
Lv LZ; Tong CQ; Lv Q; Tang XJ; Li LM; Fang QX; Yu J; Han M; Gao JQ
Int J Nanomedicine; 2012; 7():4099-107. PubMed ID: 22888246
[TBL] [Abstract][Full Text] [Related]
20. The subchronic toxicity of hydroxysafflor yellow A of 90 days repeatedly intraperitoneal injections in rats.
Liu Z; Li C; Li M; Li D; Liu K
Toxicology; 2004 Oct; 203(1-3):139-43. PubMed ID: 15363589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
